nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-84D90EE2·Framework v5.0·Pipeline v0.4·Evaluated 15 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Systematic review

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Coelho et al.Coelho, Romi, Ferreira et al.·2020·Nutrients·10.3390/nu12082296 ↗

In brief

A competent PRISMA-registered synthesis finding curcumin a promising mesalamine adjunct in ulcerative colitis, constrained by a small heterogeneous evidence base with no quantitative pooling or certainty grading.

ReliabilityCaveats3 of 4 checks completeRead the entry ↓
Abstract

The objective of this study was to systematically review the literature to verify the efficacy and safety of curcumin as a complementary therapy for the maintenance or induction of remission in patients with inflammatory bowel disease (IBD). A comprehensive search was conducted by two independent authors in MEDLINE (PubMed), Scopus, Web of Science, the Cochrane Library, Lilacs, Food Science and Technology Abstracts, and ScienceDirect. The search terms "curcumin", "curcuma", "inflammatory bowel disease", "proctocolitis", "crohn disease", and "inflammation" were combined to create search protocols. This study considered randomized controlled trials (RCTs) published in any language before March 2020 that evaluated the effects of curcumin on inflammatory activity and the maintenance or remission of IBD patients. After duplicates were removed, 989 trials were identified, but only 11 met the eligibility criteria. Five of these were considered to be biased and were excluded. Therefore, six trials were considered in this review. All the studies included in the systematic review were placebo-controlled RCTs conducted on individuals with ulcerative colitis (UC). All the RCTs reported that curcumin was well tolerated and was not associated with any serious side effects. Studies show that curcumin may be a safe, effective therapy for maintaining remission in UC when administered with standard treatments. However, the same cannot be stated for Crohn's disease due to the lack of low bias risk studies. Further studies with larger sample sizes are needed before curcumin can be recommended as a complementary therapy for UC.

Strengths · Limitations

Strengths

#methodological rigour

Transparent, registered, reproducible review protocol

The review is PROSPERO-registered, declares PRISMA compliance, and provides database-specific search strings with dual independent screening, supporting transparency and reproducibility.

↳ Methods 2.1-2.2; Table 1

#reporting

Clear tabulation of trial evidence

A detailed summary table lays out each included trial's population, intervention, dose, duration, outcome measures, and headline results, making the evidence base easy to inspect.

↳ Table 2

#contribution

Appropriately hedged, clinically relevant conclusions

The review consistently frames curcumin as a possible adjunct rather than a proven therapy and explicitly declines to extend conclusions to Crohn's disease in the absence of low-bias trials.

↳ Abstract; Discussion final paragraphs

Limitations

#methodological rigour

Quality threshold used to exclude eligible trials

Eligible trials were removed after risk-of-bias and Jadad scoring rather than retained and interpreted with quality-sensitivity, which narrows the evidence base in a non-standard way and can shift the conclusions the review reaches.

↳ Methods 2.3, 2.5; Results 3.1-3.2; Figure 1

#methodological rigour

No certainty grading or quantitative synthesis

The review performs no GRADE or equivalent certainty assessment and no meta-analysis, and offers no explicit justification for omitting pooling, limiting its ability to quantify effects or support strength-of-evidence claims for a 2020 clinical review.

↳ Methods and Results overall; Discussion

#positioning

Conclusions reach beyond sparse heterogeneous evidence

Efficacy-leaning language appears despite only six small trials with heterogeneous formulations, doses, and routes and one clearly negative trial, and an unexplained set of additional records appears in the flow diagram.

↳ Abstract; Figure 1; Discussion final paragraphs

Does this match your read? Add your assessment ↓

Nabu Commentary

Scoring was driven by the gap between a well-organized, transparently reported review and its limited synthesis methodology. The search strategy, registration, and tabulation (Methods 2.1-2.2, Table 2) are genuine strengths, but the decision to exclude otherwise eligible trials on the basis of Jadad and risk-of-bias thresholds (Methods 2.5) converts a quality assessment into an eligibility filter and narrows the evidence base in a way that affects the conclusions. The absence of any GRADE certainty assessment or meta-analysis, combined with no stated rationale for omitting pooling, holds the methodology at a competent-but-limited level. The discussion's extended treatment of bioavailability and agricultural cultivation factors (pp.9-10), while informative, is only loosely tied to the six included trials and dilutes the contextual focus. The conclusions are mostly appropriately hedged, but efficacy-leaning phrasing in the abstract and discussion sits somewhat ahead of what a small, heterogeneous evidence base with one negative trial can secure.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.1

Contribution
3.1

The review delivers a targeted, RCT-only synthesis of curcumin in IBD with the practically useful finding that low-bias evidence exists only for ulcerative colitis and not Crohn's disease. The advance is incremental because the evidence base is six trials totaling 372 participants and no quantitative pooling is attempted.

Results 3.3; Discussion final paragraphs

the same cannot be said for CD, due to the absence of RCTs with a low risk of bias

Methodological Rigour
2.9

The search is multi-database with reproducible strings, dual independent screening, and declared PRISMA/PROSPERO use, but execution falls short of best practice: the Jadad scale is used as an exclusion threshold conflating quality with eligibility, no GRADE certainty assessment is performed, and no meta-analysis or justification for its absence is given. Grey literature and trial registries are not searched.

Methods 2.2, 2.5; Table 1; Figure 2

Studies with scores < 3 were considered to have a high risk of bias and were excluded

Reporting
3.6

The paper follows a conventional, legible structure from rationale through methods, results, and discussion, with Table 2 enabling direct comparison of trial populations, interventions, and outcomes and consistently hedged language. Minor precision issues are the abstract's compressed study-flow phrasing and the undeclared 'other sources' in the PRISMA diagram.

Table 2; Figure 1; Abstract

curcumin may be a safe, effective therapy for maintaining remission in UC

Positioning
3.1

The introduction grounds the review in IBD treatment limitations and curcumin pharmacology and the discussion engages included trials directly while distinguishing UC from CD. Contextual positioning is weakened by an extended bioavailability and agricultural-factors discussion only loosely tied to the included evidence and by limited integration of certainty and heterogeneity into the bottom-line claims.

Introduction; Discussion pp.9-10 and final paragraph

The seasonality, altitude, temperature, solar incidence, water availability, and nutrient content in the soil may also alter

Lower confidence on Contribution, Positioning — domain match limited.

Reliability

Caveats3 of 4 checks


Internal CoherenceNoted

Eligible trials were excluded after risk-of-bias/Jadad assessment rather than retained and interpreted with quality-sensitivity, which alters the evidence base feeding the conclusions. The PRISMA flow diagram reports 57 additional records from unspecified sources not described in the Methods, and some conclusion language implies efficacy beyond what six small, heterogeneous RCTs with one negative trial support.

Research ConductClean

PROSPERO registration (CRD42019104827) and PRISMA use are declared and conflicts of interest are declared as none; no ethics approval is required for a review of published literature. Absence of a data-availability statement or shared extraction dataset is a transparency limitation but not a conduct concern.

Flags: 2 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceSynthesis
Route to useSuggested
AdvanceConsolidates
BeneficiariesSmall
CitationsFWCI 6.9
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim rests on six small placebo-controlled RCTs with heterogeneous doses and formulations, and the authors state larger trials are needed before recommending curcumin.

From the paper
“Studies show that curcumin may be a safe, effective therapy for maintaining remission in UC when administered with standard treatments.”

The paper names a real-world use of its findings—curcumin as a complementary therapy for UC—but does not specify who would act on it or in what decision setting.

Pathway

Clinicians treating ulcerative colitis could add curcumin to standard mesalamine therapy once larger confirmatory trials establish optimal dose and formulation.

Barrier

Small sample sizes, varied formulations and doses, and the absence of an established therapeutic protocol prevent clinical recommendation of curcumin.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis

    Milad Sabzevary-Ghahfarokhi, Mojtaba Shohan, Hedayatollah Shirzad, et al. · 2018 · Basic medicine

    Primary claim

    Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1.

    Unsupported
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. Curcumin for maintenance of remission in ulcerative colitis

    Kumar, Ahuja, Sankar, et al. · 2012 · Clinical medicine

    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  3. Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study

    Yanai, Salomon, Lahat, et al. · 2023 · Basic medicine

    Evidence Score
    3.1±0.2
    Reliability
    Caveats

How the rubric works →